Rarebase
Rarebase operates an AI-powered drug discovery platform combining proprietary transcriptomic data and Conductor AI models to predict gene responses to novel compounds, serving pharmaceutical and biotechnology companies through licensing and co-development partnerships.
- Company typePrivate
- Founded2020
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Rarebase does
Rarebase operates an AI-powered drug discovery platform built around transcriptomic analysis and is headquartered in Palo Alto, California. The platform screens thousands of small molecules across 20,000 genes in a wet lab and feeds the resulting expression data into proprietary Conductor AI models that predict gene responses to billions of novel compound structures. Combined with cell atlases, these data form the Transcriptomic Perturbation Atlas, a proprietary whole-transcriptome dataset used to surface therapeutic hypotheses across human diseases. Validation of AI-predicted compounds is performed in-house, creating a closed-loop discovery engine intended to accelerate candidate identification relative to traditional screening approaches. The platform is positioned as an enterprise B2B offering for pharmaceutical and biotechnology customers, addressing high industry failure rates and the limited throughput of conventional small-molecule discovery. The company states its pipeline contains active therapeutic candidates in the discovery stage. The firmographic input describes the entity as "Biomedical R&D for Rare Disease" founded in 2020 with 11–50 employees, while the operational data describes an AI transcriptomics platform consistent with Transcripta Bio's public profile; this analysis reflects the integrated dataset as supplied.
The core product surface comprises four interlocking components: (1) the Transcriptomic Perturbation Atlas, a proprietary high-resolution transcriptomic dataset built from diverse small molecules and combined with cell atlases; (2) Conductor AI, the in-silico predictive modeling layer that forecasts gene expression responses to novel compound structures; (3) a proprietary whole-transcriptome resolution analytics platform capable of generating millions of therapeutic hypotheses per screening run; and (4) an in-house wet lab that synthesizes and validates AI-selected compounds. Together these components are presented as an integrated end-to-end discovery engine rather than a point-tool offering.
Revenue is generated through B2B enterprise biotech deal structures — licensing arrangements, co-development partnerships, and potential acquisition or out-licensing of drug candidates — with pricing following industry-standard convention (upfront payments, development milestones, and royalties on successful commercialization). Go-to-market is direct enterprise field sales targeting pharma and biotech decision-makers globally; the company maintains corporate website, LinkedIn, and Twitter presences for top-of-funnel awareness. The company was named to TIME100 Most Influential Companies of 2024.
Rarebase firmographics
Firmographics- Name
- Rarebase
- Legal name
- Transcripta Bio, Inc.
- Website
- https://rarebase.org
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Rarebase operates an AI-powered drug discovery platform combining proprietary transcriptomic data and Conductor AI models to predict gene responses to novel compounds, serving pharmaceutical and biotechnology companies through licensing and co-development partnerships.
- Ownership category
- akta.pro rank
Where Rarebase is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Rarebase business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Drug Discovery Partnerships and Licensing: The company develops therapeutic candidates through its AI-powered platform and likely generates revenue through licensing deals, co-development partnerships, and potential acquisition or out-licensing of drug candidates to pharmaceutical companies
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Rarebase product offering
Product offeringCore offering
Rarebase (operating as Transcripta Bio) operates an AI-powered drug discovery platform that combines high-throughput laboratory screening with proprietary machine learning models to map chemical structures to gene expression responses across 20,000 genes. The company screens thousands of molecules to build a high-resolution transcriptomic perturbation atlas and uses its Conductor AI models to predict gene response to billions of novel compounds. Validated therapeutic candidates are then synthesized and tested in-house in its wet lab, with candidates licensed or partnered with pharmaceutical and biotechnology companies.
Product overview
Transcripta Bio offers an integrated AI-powered drug discovery platform centered on transcriptomic analysis. The core offering consists of a high-resolution transcriptomic perturbation atlas combined with Conductor AI models for predicting gene expression responses to novel compounds. The platform is supported by proprietary analytics tools providing whole-transcriptome resolution and an in-house wet lab for molecule synthesis and validation. Together, these components enable the company to generate millions of therapeutic hypotheses per screening run.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Discovery Platform
Quantifiable outcome
- Millions of therapeutic hypotheses unlocked per screen
Companies that use Rarebase
Customer profileSegments1 record
Ideal customer profiles1 record
Rarebase technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Rarebase partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights4 records
Rarebase competitors and assessment
Company assessmentBroad incumbents
- Owkin: AI biotech company combining multimodal patient data with ML to accelerate drug discovery and development. Comparable as an AI-driven platform serving pharma partnerships, though broader in scope with clinical and diagnostic AI capabilities.
- Schrödinger: Computational chemistry and materials science platform combining physics-based simulation with ML. Comparable as a broader computational drug-discovery player serving pharma with predictive modeling and software-based discovery workflows.
Direct peers
- Atomwise: AI-driven small molecule drug design company using structure-based prediction. Comparable as an AI-first discovery platform that generates novel compounds for pharma partnerships and licensing deals.
- Insitro: Machine learning-driven drug discovery company combining high-throughput biology with predictive models. Comparable in using proprietary data generation and AI to identify novel therapeutic candidates and partner with pharmaceutical companies.
- Lantern Pharma: AI-driven oncology drug development company using machine learning to identify responders and accelerate clinical development. Comparable as a smaller AI-driven therapeutics company pursuing partnership and licensing models.
- Exscientia: AI-native pharma company using precision engineering and active learning to accelerate small-molecule drug discovery. Comparable in leveraging AI to predict compound behavior and partnering with pharma for clinical development.
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Directly comparable in leveraging proprietary experimental data and ML models to generate therapeutic hypotheses across multiple disease areas.
Emerging players
- Isomorphic Labs: Alphabet-owned AI drug discovery company applying frontier AI to predict biological behavior of molecules. Comparable as an AI-native discovery platform with wet-lab validation loops and pharma partnership ambitions.
- Cradle Bio: AI platform for protein and biologics engineering using generative models. Comparable as an emerging ML-driven discovery platform that designs novel biological molecules and partners with larger biopharma.
- Generate Biomedicines: AI-driven biologics platform using generative machine learning to design novel protein therapeutics. Comparable in combining proprietary ML with wet-lab validation to expand the universe of addressable therapeutic targets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Rarebase social profiles
Digital presenceRarebase financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rarebase leadership team
Management profileNumber of profiles
Profiles3 records
Rarebase funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rarebase M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rarebase
What does Rarebase do?
Rarebase (operating as Transcripta Bio) operates an AI-powered drug discovery platform that combines high-throughput laboratory screening with proprietary machine learning models to map chemical structures to gene expression responses across 20,000 genes. The company screens thousands of molecules to build a high-resolution transcriptomic perturbation atlas and uses its Conductor AI models to predict gene response to billions of novel compounds. Validated therapeutic candidates are then synthesized and tested in-house in its wet lab, with candidates licensed or partnered with pharmaceutical and biotechnology companies.
Is Rarebase a public or private company?
Rarebase is a private company. It is classified as unknown and is currently operating.
When was Rarebase founded?
Rarebase was founded in 2020. It employs 11 to 50 people.
Where is Rarebase based?
Rarebase is headquartered in Palo Alto, United States, in the North America region.
How does Rarebase make money?
One revenue line is on record: drug Discovery Partnerships and Licensing.
Who are Rarebase's main competitors?
Broad incumbents on record are Owkin and Schrödinger. Direct peers are Atomwise, Insitro, Lantern Pharma, Exscientia and Recursion Pharmaceuticals. Emerging players are Isomorphic Labs, Cradle Bio and Generate Biomedicines.
Does Rarebase have an API?
No public API is recorded for Rarebase.